What's Happening?
Community oncology practices are experiencing significant financial pressure due to a confluence of policy changes, including drug price negotiation, Medicaid coverage adjustments, insurer utilization management, and 340B reform. According to oncology policy leaders
at The American Journal of Managed Care’s annual Patient-Centered Oncology Care conference, reimbursement could decrease by 30% to 40% without legislative intervention. The Part D component of the Inflation Reduction Act (IRA) is already complicating planning, with Medicare-negotiated prices for several significant oral oncolytics, such as palbociclib (Ibrance), enzalutamide (Xtandi), pomalidomide (Pomalyst), and acalabrutinib (Calquence), set to take effect in 2027. These changes are forcing practices to adapt to new financial realities and operational challenges. Insurer utilization management, particularly prior authorization and step therapy, continues to burden practices, despite pledges for reform from the Department of Health and Human Services (HHS).
Why It's Important?
The financial strain on community oncology practices has significant implications for cancer care in the U.S. These practices often provide accessible, localized care, and their potential closure or consolidation could limit patient access to essential treatments. The reduction in reimbursement, driven by policies like Medicare drug price negotiation, could force practices to cut services, reduce staff, or even close, leading to a more centralized, hospital-based cancer care system. This shift could disproportionately affect rural areas and underserved communities, where community oncology practices are often the primary providers of specialized cancer treatment. Furthermore, the ongoing challenges with prior authorization and step therapy create administrative burdens and can delay patient access to necessary medications, potentially impacting treatment outcomes and increasing healthcare costs in the long run due to more advanced disease progression. The stability of community oncology is crucial for maintaining a robust and equitable cancer care infrastructure.
What's Next?
Panelists at the conference urged Congress to intervene by reducing unnecessary utilization management and ensuring comprehensive coverage to support the health of the community oncology system. There are ongoing legislative efforts, with about half a dozen bills addressing 340B reform pending in Congress. A CMS proposal to pay for 340B-acquired drugs at average sales price minus 33.4% next year, a significant reduction from the previous ASP plus 6%, is also on the horizon. This proposal aims to level the playing field but raises questions about the future of health systems reliant on 340B revenue and whether it will drive further consolidation. The implementation of Medicare-negotiated drug prices in 2027 for key oncology drugs will be a critical development, potentially leading to further adjustments in practice operations and patient access strategies. The industry will likely continue to advocate for legislative fixes to mitigate the financial pressures.
Beyond the Headlines
The challenges faced by community oncology practices highlight a broader tension within the U.S. healthcare system: the balance between controlling drug costs and ensuring the viability of healthcare providers. While drug price negotiations aim to make medications more affordable for beneficiaries, they can inadvertently squeeze the financial margins of the providers who administer these drugs. This situation raises ethical questions about the sustainability of specialized medical care and the potential for policies designed to benefit patients to inadvertently harm the infrastructure that delivers that care. The debate over 340B reform also touches on the role of federal programs in supporting vulnerable patient populations and the potential for these programs to be exploited or to create unintended market distortions. The long-term implications could include a significant restructuring of cancer care delivery, with fewer independent practices and a greater reliance on larger health systems, potentially impacting patient choice and the personalized nature of care.
